Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
issn: 1664-3224
- Schlagwort
-
T-Lymphozyt
Akute Leukämie
Transplantat-Wirt-Reaktion
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2019
- Urheber
- DOI
-
10.3389/fimmu.2018.03179
- URN
-
urn:nbn:de:bsz:25-freidok-1491974
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Köhler, Natalie
- Zeiser, Robert
- Universität
Entstanden
- 2019
Ähnliche Objekte (12)
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Advances in understanding the pathogenesis of graft‐versus‐host disease
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Advances in understanding the pathogenesis of graft‐versus‐host disease
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Advances in understanding the pathogenesis of graft‐versus‐host disease